Timothy Yap
Editor-in-Chief
Clinician Scientist and Consultant in Medical Oncology,The Institute of Cancer Research (ICR) and Royal Marsden Hospital (RMH) in London
Timothy Yap is a Clinician Scientist and Consultant in Medical Oncology in the Early Phase Drug Development and Lung Cancer Units, and Cancer Biomarkers Laboratory Group at The Institute of Cancer Research (ICR) and Royal Marsden Hospital (RMH) in London. His research includes the first-in-human development of molecularly targeted agents and their acceleration through clinical studies, using novel predictive and pharmacodynamic biomarkers. Dr Yap?s laboratory interests include the development of tumours, plasma DNA and circulating tumour cells as predictive biomarkers in clinical trials, with a specialist interest in lung cancer. Dr Yap gained his BSc degree with First Class Honours in Pathology at Imperial College London, and was awarded the Huggett Memorial Prize. He went on to attain a medical degree from Imperial College, before completing general medical training in Oxford. In 2005, Dr Yap joined ICR/RMH, where he undertook a Clinical Fellowship in the Drug Development Unit, before completing a PhD in Molecular Pharmacology in the Division of Cancer Therapeutics at the ICR, under a Cancer Research UK PhD Fellowship. Dr Yap subsequently completed his specialist training in Medical Oncology at RMH and was awarded a NIHR Academic Clinical Lectureship in Medical Oncology. In the past, Dr Yap has been a recipient of the McElwain Prize from the UK Association of Cancer Physicians and Young Investigator Award from the US Prostate Cancer Foundation, and has also received awards from ASCO, AACR, EORTC and ETOP. He has published widely in peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology and Nature Reviews Cancer.
Early Phase Drug Development, Lung cancer, Predictive biomarkers in clinical trials
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 
